VLA4 Gene Polymorphism and Susceptibility to Multiple Sclerosis in Slovaks. 2015

V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
Institute of Immunology, School of Medicine, Comenius University in Bratislava, Slovakia.

Multiple sclerosis (MS) is an inflammatory autoimmune disease occurring in genetically sensitive individuals. As migration of immune cells into the CNS is facilitated by the Very Late Antigen 4 (VLA-4) integrin molecule, the VLA4 gene may be considered as a plausible candidate genetic risk factor for susceptibility to MS. Therefore, the objective of our study was to investigate the association between two genetic polymorphisms located in the VLA4 gene and the risk of multiple sclerosis. One hundred seventeen MS patients and 165 control subjects from Slovakia were genotyped for VLA4 gene SNP polymorphisms at positions 269 (C/A) and 3061 (A/G). The same study cohorts were also genotyped for the rs3135388 polymorphism tagging the HLA-DRB1*15:01 allele, which is a known genetic factor associated with susceptibility to develop MS in many populations. Our findings show for the first time that the rs3135388 polymorphism is a strong risk factor for MS in the Slovak population. Investigation of the VLA4 gene polymorphisms revealed a significantly higher frequency of the 3061AG genotype in MS patients compared to the controls (P ≤ 0.05). We suggest that the 3061AG polymorphic variant is an independent genetic risk factor for MS development in our population as it was significantly associated with this disease. The association was also confirmed after applying multivariate logistic-regression analysis adjusted for gender, age and HLA-DRB1*15:01 positivity as possible influencing factors.

UI MeSH Term Description Entries
D008297 Male Males
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D005260 Female Females
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D059811 HLA-DRB1 Chains A subtype of HLA-DRB beta chains that includes over one hundred allele variants. The HLA-DRB1 subtype is associated with several of the HLA-DR SEROLOGICAL SUBTYPES. HLA DRB1,HLA-DRB1,HLA-DRB1 Antigen,Antigen, HLA-DRB1,Chains, HLA-DRB1,HLA DRB1 Antigen,HLA DRB1 Chains
D018154 Slovakia Created 1 January 1993 as a result of the division of Czechoslovakia into the Czech Republic and Slovakia. Slovak Republic

Related Publications

V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
October 2023, Neurological research,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
March 1995, Human immunology,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
April 2015, Neurological research,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
March 2014, Noro psikiyatri arsivi,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
October 1999, Neurology,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
August 2016, Neurological research,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
October 2002, Annals of neurology,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
October 2010, PloS one,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
July 2002, Journal of neuroimmunology,
V Ďurmanová, and I Shawkatová, and J Javor, and Z Párnická, and D Čopíková-Cundráková, and P Turčáni, and I Lisá, and B Gajdošechová, and M Buc, and M Bucová
July 2008, Journal of neuroimmunology,
Copied contents to your clipboard!